BioSpace News Archive

Xenon Pharmaceuticals to Present at the Stifel 2023 CNS Days

Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the virtual Stifel 2023 CNS Days taking place March 28-29, 2023.

March 22, 2023
·
1 min read
IRLAB: Invitation to symposium on Parkinson’s Disease and its Management Dilemma at the AD/PD(TM) 2023 on March 31, 2023

IRLAB Therapeutics AB announced an invitation to its industry symposium at the AD/PD™ 2023 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders on Friday, March 31, 2023.

March 22, 2023
·
2 min read
XNK presents at the 8th Innate Killer Summit in La Jolla, San Diego

XNK Therapeutics AB announced its extensive participation at the 8th Annual Innate Killer Summit in La Jolla, San Diego, CA, March 28-30.

March 22, 2023
·
2 min read
Drug Development

Alzheon to Present Biomarker, Brain Preservation and Clinical Effects of Oral Tablet ALZ-801 (Valiltramiprosate) at Upcoming AD/PD 2023 Conference in Gothenburg, Sweden

Alzheon, Inc. announced that it will be presenting interim findings from an ongoing Phase 2 study evaluating ALZ-801 tablet at the upcoming AD/PD 2023 Conference to be held from March 28 – April 1, 2023 in Gothenburg, Sweden.

March 22, 2023
·
9 min read
Pharm Country

Tonix Pharmaceuticals to Present at the 2023 Virtual March Investor Summit

Tonix Pharmaceuticals Holding Corp. announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present at the Virtual March Investor Summit on Wednesday, March 29, 2023, at 9:00 a.m. ET.

March 22, 2023
·
4 min read
FDA

FDA Approves First-in-class Evkeeza® (evinacumab-dgnb) for Young Children with Ultra-rare Form of High Cholesterol

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration (FDA) has extended the approval of Evkeeza® (evinacumab-dgnb) as an adjunct to other lipid-lowering therapies to treat children aged 5 to 11 with homozygous familial hypercholesterolemia (HoFH).

March 22, 2023
·
16 min read
Biotech Bay

ASLAN Pharmaceuticals to Participate in Fireside Chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

ASLAN Pharmaceuticals today announced Dr. Carl Firth, CEO, will be available for one-on-one meetings and participate in a fireside chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference being held on March 30, 2023.

March 22, 2023
·
1 min read
Business

Remix Therapeutics Appoints Robert Gagnon as Chief Financial Officer

Remix Therapeutics today announced the appointment of Robert Gagnon as Chief Financial Officer.

March 22, 2023
·
2 min read
Business

BioLineRx Reports 2022 Financial Results and Recent Corporate and Portfolio Updates

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today reported its audited 2022 annual financial results for the year ended December 31, 2022, and provided recent corporate and portfolio updates.

March 22, 2023
·
15 min read
Biotech Bay

Axon Therapies Cohort Study Extends Benefit to 6 months with Early Clinical Data from REBALANCE-HF Randomized Clinical Trial

Axon Therapies today announced positive 6-month results from a roll-in cohort for their feasibility IDE trial, REBALANCE-HF.

March 22, 2023
·
3 min read